Aurobindo Pharma USA Inc. has successfully acquired Lannett Company, Inc., now operating as Lannett Company LLC. This strategic move aims to boost Aurobindo's US market presence and integrate over 400 employees.
Aurobindo Pharma Completes Lannett Acquisition
Lannett Company, Inc. is now a wholly owned subsidiary of Aurobindo Pharma USA Inc. (APUSA) effective June 29, 2026.
Reader Takeaway: Strengthened US market presence through strategic acquisition; integration efficiency is key.
What just happened
Aurobindo Pharma USA Inc. (APUSA) has finalized the acquisition of Lannett Company, Inc. The deal, which received U.S. Federal Trade Commission approval on June 18, 2026, officially closed on June 29, 2026. Lannett Company, Inc. will now operate under the name Lannett Company LLC and is a wholly owned subsidiary of APUSA.
Why this matters
This acquisition is a significant step in Aurobindo Pharma's inorganic growth strategy, aimed at enhancing its operational footprint and market share within the United States. It brings over 400 new employees into the Aurobindo group, bolstering its talent pool and operational capabilities in the US.
The backstory
The acquisition of Lannett Company, Inc. was a planned strategic move by Aurobindo Pharma to expand its presence in the US generics market. The regulatory approval process, including from the FTC, was a crucial step preceding the completion.
What changes now
Lannett Company, Inc. is now integrated into Aurobindo's US operations under the new name Lannett Company LLC. The company is focused on ensuring continuity of care for patients and customers, maintaining trusted partnerships, and integrating the new employees to leverage their expertise.
Risks to watch
Investors will be watching the efficiency of the integration process and the company's ability to achieve the intended synergies from the acquisition. Any disruptions to patient access or partner relationships during the transition could pose risks.
Peer comparison
Aurobindo Pharma operates in the competitive generics and specialty pharmaceuticals market in the US, facing established players. This acquisition aims to strengthen its competitive position.
Context metrics (time-bound)
The acquisition officially became effective on June 29, 2026, following FTC approval on June 18, 2026. Over 400 employees are being integrated.
What to track next
Future updates on the operational integration of Lannett Company LLC, realization of synergies, and its contribution to Aurobindo's overall US market performance will be key for investors.